A review of new atypical antipsychotic launches in the United States.

Jeff Ventimiglia, Amir H Kalali, Leslie Citrome
{"title":"A review of new atypical antipsychotic launches in the United States.","authors":"Jeff Ventimiglia,&nbsp;Amir H Kalali,&nbsp;Leslie Citrome","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and iloperidone (Fanapt(®), Vanda Pharmaceuticals Inc./Novartis), two new atypical antipsychotics to launch in the United States market in October 2009 and January 2010, respectively. In the first 12 months following the asenapine launch, and in the nine months since the iloperidone launch, asenapine and iloperidone have secured 0.22 and 0.10 percent of the total prescription market; however, both products nearly double those respective shares when total prescriptions are isolated to new patient prescriptions (0.44% for asenapine and 0.17% for iloperidone). Since launch, asenapine has shown stronger signs of growth, largely attributed to its approval in multiple indications as compared to iloperidone's single indication.</p>","PeriodicalId":20822,"journal":{"name":"Psychiatry (Edgmont (Pa. : Township))","volume":"7 12","pages":"13-5"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028460/pdf/PE_7_12_13.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry (Edgmont (Pa. : Township))","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and iloperidone (Fanapt(®), Vanda Pharmaceuticals Inc./Novartis), two new atypical antipsychotics to launch in the United States market in October 2009 and January 2010, respectively. In the first 12 months following the asenapine launch, and in the nine months since the iloperidone launch, asenapine and iloperidone have secured 0.22 and 0.10 percent of the total prescription market; however, both products nearly double those respective shares when total prescriptions are isolated to new patient prescriptions (0.44% for asenapine and 0.17% for iloperidone). Since launch, asenapine has shown stronger signs of growth, largely attributed to its approval in multiple indications as compared to iloperidone's single indication.

美国新推出的非典型抗精神病药物综述。
在这篇文章中,我们调查了阿塞纳平(Saphris(®),默克公司)和伊operidone (Fanapt(®),万达制药公司/诺华公司)两种新的非典型抗精神病药物上市后的零售处方趋势,这两种药物分别于2009年10月和2010年1月在美国市场上市。在阿塞那平上市后的前12个月和伊operidone上市后的9个月里,阿塞那平和伊operidone分别占据了处方总市场的0.22%和0.10%;然而,当将总处方分离到新患者处方时,这两种产品的份额几乎是各自的两倍(阿塞那平为0.44%,伊哌啶酮为0.17%)。自上市以来,阿塞纳平表现出更强劲的增长迹象,这主要归功于与伊哌啶酮的单一适应症相比,阿塞纳平的多适应症获批。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信